Group 1: Financial Performance - In Q1 2025, the company achieved operating revenue of 2.687 billion CNY, a year-on-year increase of 26.07% [2] - The net profit attributable to shareholders was 466 million CNY, reflecting a year-on-year growth of 24.04% [2] Group 2: Growth Strategies - The company will focus on developing both oil and non-oil industries to support dual business growth [2] - There is a commitment to enhance the overseas market share, aiming for a robust dual-market development structure [2] Group 3: Industry Outlook - The demand for unconventional oil and gas resources is expected to rise due to the gradual depletion of conventional resources and increasing global energy needs [3] - The company anticipates more business opportunities in oil and gas extraction equipment and services [3] Group 4: Supply Chain Management - The company has established diversified procurement channels globally to mitigate the impact of trade tensions, particularly regarding the import of turbine engines from the U.S. [3] - Proactive measures have been taken to stockpile essential raw materials and major components to ensure supply chain stability [3] Group 5: Market Orders and R&D - As of the end of Q1, the company reported a year-on-year increase in overseas orders [3] - Continuous attention is being given to new technology research and development, with timely disclosures planned for significant advancements [3]

股票代码：300436 股票简称：广生堂 福建广生堂药业股份有限公司投资者关系活动记录表 编号：2025-002 7.高管您好。请问贵公司本期财务报告中，盈利表现如何？谢谢。 | | 答：尊敬的投资者，您好！2024 年度，受集采政策持续影响，乙肝产品毛利 | | --- | --- | | | 率承压，且前期建设项目转固和药品获批上市导致无形资产增加，相应资产折旧 | | | 及摊销增加，此外市场拓展及团队建设强化相关投入增加，叠加创新药战略投入 | | | 维持高强度、财务费用增加及资产减值损失计提等综合影响。公司 2024 年公司净 | | | 利润为-1.72 亿元，归属于母公司股东的净利润为-1.56 亿元，归属于上市公司股 | | | 东净利润仍然亏损，但公司经营质量有所改善，营收继续保持增长，综合毛利率 | | | 提升超过 4 个百分点，经营活动产生的现金流量净额转正，业绩亏损同比大幅收 | | | 窄 55.16%。2025 年一季度业绩同比下降，主要因抗新冠创新药泰中定 2025 年一 | | | 季报贡献营收较小。剔除泰中定波动影响后，2025 年一季度公司营业收入继续保 | | | 持 ...

4、高管您好，请问贵公司未来盈利增长的主要驱动因素有哪 些？谢谢。 | 投资者关系活 | □特定对象调研□分析师会议 | | | --- | --- | --- | | 动类别 | □媒体采访√业绩说明会 | | | | □新闻发布会□路演活动 | | | | □现场参观 | | | 参与单位名称 | 投资者网上提问 | | | 及人员姓名 | | | | 时间 | 月 日 (周五) 下午 2025 4 25 15:00~17:00 | 年 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 采用网络远程的方式召开业绩说明会 | | | 上市公司接待 | 1、董事、董事长寇相东 | | | 人员姓名 | 2、董事、总经理徐旭日 | | | | 3、董事、副总经理、财务负责人李艳霞 | | | | 4、董事、董事会秘书张莎 | | | | 5、独立董事王京 | | | | 投资者提出的问题及公司回复情况 | | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | | 1、公司在 2024 年履行环境保护和社会责任方面有哪些具体举 | ...

证券简称：宣亚国际 证券代码：300612 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（请文字说明其他活动内容） 参与单位名称及 人员姓名 参加公司 2024 年度网上业绩说明会的投资者 时间 2025 年 4 月 25 日（星期五）15:00-16:00 地点 全景网（http://rs.p5w.net） 上市公司 接待人员姓名 董事长、首席执行官（总裁）：任翔先生 副总裁、财务总监：张靖女士 副总裁、董事会秘书：汪晓文女士 独立董事：张鹏洲先生 保荐代表人：管仁昊先生 投资者关系活动 主要内容介绍 1、领导，您好！我来自四川大决策 公司业绩已经连续 2 年亏损，营收也 连续 2 年下滑，2025 年会有改善吗？ 尊敬的投资者您好，公司 2025 年第一季度实现营业收入 11,178.87 万元， 归属于上市公司股东的净利润亏损 402.94 万元，较上年同期亏损收窄 79.77%， 剔除股份支付费用影响后归属于上市公司股东的净利润为 680.97 万元，同比 增长 134.19%。同时，公司在报告期内持续提升运营效率，加强各类 ...

久祺股份有限公司投资者关系活动记录表 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | | --- | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | | □ 新闻发布会 □ 路演活动 | | | | 现场参观 □ | | | | 其他 （请文字说明其他活动内容） □ | | | 参与单位名称及 | 投资者网上提问 | | | 人员姓名 | | | | 时间 | 2025 年 4 月 25 (周五) 下午 15:00~16:00 | 日 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 采用网络远程的方式召开业绩说明会 | | | 上市公司接待人 | 1、董事长李政 | | | 员姓名 | 2、董事会秘书兼财务总监雍嬿 | | | | 3、独立董事祝立宏 | | | | 4、保荐代表人林苏钦 投资者提出的问题及公司回复情况 | | | | 公司就投资者在本次说明会中提出的问题进行了回复： 1、领导，您好！我来自四川大决策 | | | | 请问：久祺股份的募集资金主要投向轻量化共享单车、高端 | | | ...

Group 1: Trade Impact and Response - The company faces challenges in U.S. export trade due to the U.S.-China trade war, leading to uncertainties. Future strategies include strengthening overseas market presence and supply chain adjustments to mitigate impacts [3] - The "reciprocal tariff" policy affects the company's export business, with approximately 30% of consolidated revenue from overseas OEM operations. The U.S. market holds a significant share, and the policy impacts orders from Chinese factories, while Thai factories remain unaffected [3] - Domestic market trends show a shift towards local brand replacement, accelerated by the trade war, with the company aiming to fill market gaps and enhance brand strength [3] Group 2: Growth Strategies - The company's growth is primarily driven by its proprietary brand business, with OEM operations decreasing in proportion. Revenue and profit margins from domestic brands are on the rise [4] - Key factors for growth include product structure optimization, increasing direct sales, multi-brand strategy, and supply chain enhancements through new and smart factory investments [4] Group 3: Research and Development - The company has invested over 200 million CNY in R&D over the past three years, with 329 domestic patents granted by 2024, focusing on core areas like fresh meat additives and nutrient release technologies [4] - A collaborative innovation model across multiple R&D centers strengthens technological barriers, creating a complete cycle from basic research to market application [4] Group 4: Shareholder Returns - In 2024, the company plans to distribute over 200 million CNY in cash dividends, representing 32.02% of the annual net profit attributable to shareholders, aiming to enhance investor returns and ensure stable profit distribution policies [4]

Group 1: LED Business Developments - In 2024, the company recognized an asset impairment loss of CNY 595 million in its LED business due to intensified competition [2] - For 2025, the company aims to reduce losses or achieve profitability in the LED sector through product structure adjustments and cost-cutting measures [2] Group 2: Precision Manufacturing Progress - The company has significantly improved its precision manufacturing business, particularly in the new energy sector, with multiple partnerships established with leading domestic and international electric vehicle manufacturers [3] - The business situation in 2024 is expected to show marked improvement compared to previous years, with some clients entering mass production in Q4 [3] Group 3: Future Strategic Directions - The company will continue to deepen its "dual-drive" strategy, focusing on core products like electronic circuits and precision components while expanding into emerging markets [3] - Increased R&D investment will target cutting-edge technologies to enhance market share and brand influence [3] Group 4: Financial Performance Overview - In 2024, the electronic circuit revenue is projected to grow steadily, while the LED segment's loss reduction target was not met [3] - The touch display and precision manufacturing divisions have shown signs of profitability, although overall results remain close to breakeven after accounting for integration costs [3] Group 5: Market Outlook and Challenges - The company anticipates stable demand for consumer electronics despite potential trade policy risks, maintaining its position as the second-largest global flexible printed circuit board (FPC) manufacturer [4] - The Thai factory is expected to achieve mass production in the second half of the year, contingent on successful product validation [4]

证券代码：002406 证券简称：远东传动 许昌远东传动轴股份有限公司 远东传动 2024 年度业绩说明会 投资者活动记录表 编号：2025-001 | | □特定对象调研 □分析师会议 | | | | --- | --- | --- | --- | | 投资者关系活动 | □媒体采访 √业绩说明会 | | | | 类别 | □新闻发布会 □路演活动 | | | | | □现场参观 □电话会议 | | | | | （请文字说明其他活动内容） □其他： | | | | 参与单位名称 | 远东传动2024年度业绩说明会采用网络远程方式进行，面向全 | | | | 及人员姓名 | 体投资者 | | | | 时间 | 2025 年 4 月 25 日 15:00-17:00 | | | | 地点 | 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈" | | | | | 栏目 | | | | 公司接待人员 | 主持人：远东传动 | | | | | 董事长：刘延生 | | | | | 总经理：刘娅雪 | | | | 姓名 | 董秘：刘硕 | | | | | 财务总监：李茹 | | | ...

Company Overview - Beijing Yihe Jiaye Medical Technology Co., Ltd. was established in 2001 and launched its first multi-channel sleep monitor in 2003. The company focuses on providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [2][3]. - The company is a leading domestic manufacturer of non-invasive ventilators and masks, with products sold in over 100 countries and regions, and has obtained multiple certifications including NMPA, FDA, and CE [2][3]. Research and Development - As of December 31, 2024, the company holds 633 domestic patents, including 107 invention patents, 390 utility model patents, and 136 design patents. It also has 202 international patents, with 39 in the USA and 30 in Europe [3]. Financial Performance (Q1 2025) Domestic Market - Domestic revenue increased by 43.03% year-on-year and 48.79% quarter-on-quarter. The gross margin improved by 7.10% year-on-year and 15.87% quarter-on-quarter, indicating stable domestic operations [4][7]. - Domestic business revenue reached 0.96 billion CNY, with a gross margin of 51.51% [7]. International Market - International revenue reached 1.70 billion CNY, a year-on-year increase of 35.48%, primarily driven by the clearance of inventory in the US respiratory market [6]. - The gross margin for international operations was 48.47%, with a 4.56% increase in the US market [6]. Overall Financials - Total revenue for Q1 2025 was 2.65 billion CNY, reflecting a 9.90% quarter-on-quarter increase and a 38.11% year-on-year increase. Net profit was 0.72 billion CNY, with a significant quarter-on-quarter increase of 137.70% and a year-on-year increase of 44.11% [5]. Product Performance - Revenue from home ventilators reached 1.76 billion CNY in Q1 2025, with a 15.71% quarter-on-quarter increase and a 62.80% year-on-year increase [8]. - Revenue from consumables was 0.81 billion CNY, with a 3.21% quarter-on-quarter increase and a 7.46% year-on-year increase, significantly contributed by the US and European markets [9]. Brand Strategy - The company has rebranded from "Yihe Jiaye" to "Ruimaite" to align its corporate name with its product brand, enhancing brand recognition and reducing confusion among consumers and investors [9][10]. - Future branding efforts will focus on increasing market awareness through various channels, including exhibitions, academic exchanges, and social media marketing [9]. Technological Integration - The company is exploring the integration of brain-computer interface technology with its respiratory products, which could enhance sleep monitoring and intervention capabilities [11][12].

300756 金马游乐-投资者关系活动记录 广东金马游乐股份有限公司 投资者关系活动记录表 | 投资者关系活动类别 | □特定对象调研 □分析师会议 □媒体采访 | | --- | --- | | | ■业绩说明会 □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 时间 | 2025 年 4 月 25 日 15:00-17:00 | | 地点 | "价值在线"平台（www.ir-online.cn） | | 参与单位名称 | 线上参与公司 2024 年度网上业绩说明会的全体投资者 | | | 金马游乐 董事长 邓志毅 金马游乐 董事、总经理 高庆斌 | | 公司接待人员姓名 | 金马游乐 副总经理、董事会秘书 曾庆远 | | | 金马游乐 独立董事 何卫锋 | | | 金马游乐 财务总监 郑彩云 | | | 民生证券 保荐代表人 张勇 | | | 2024 年度网上业绩说明会主要内容： | | | （一）公司 2024 年度经营情况回顾及未来展望 | | | 2024 年，公司发展稳中有进，面对外部环境的诸多不确定性，公 | | | 司坚持稳健经营策略，以有效管控风险、保障公司权益为前提，扎实 ...